EXICURE, INC.
Early-stage biotech developing nucleic acid therapies based on SNA technology.
XCUR | US
Overview
Corporate Details
- ISIN(s):
- US30205M1018
- LEI:
- Country:
- United States of America
- Address:
- 2430 N. HALSTED ST., 60614 CHICAGO
- Website:
- https://www.exicuretx.com/
Description
Exicure, Inc. is an early-stage biotechnology company that has historically focused on developing nucleic acid therapies based on its proprietary Spherical Nucleic Acid (SNA) technology. The company's platform is designed to create therapeutics that target ribonucleic acid (RNA) to address validated targets. Past development efforts have concentrated on neurological disorders and other conditions, leveraging the SNA architecture for gene silencing and immunomodulatory applications.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
|
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB
Full Filing History RestrictedAccess to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset. |
|||||
Automate Your Workflow. Get a real-time feed of all EXICURE, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for EXICURE, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for EXICURE, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
